Immunotherapy after Chemo-Radiation may keep esophageal cancer at bay
NCT ID NCT07246330
First seen Nov 25, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This phase 3 study tests whether the immunotherapy drug toripalimab, given after initial chemo-immunotherapy and radiation, can delay cancer growth in people with advanced esophageal cancer that hasn't spread further. About 340 adults whose cancer responded or remained stable after initial treatment will be randomly assigned to receive toripalimab or just observation. The goal is to see if toripalimab improves how long patients live without their cancer worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.